How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
Multiple myeloma treatment: Why we still need novel scientific research.
Multiple myeloma (MM) is an incurable form of hematological cancer affecting…